GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease

2021 ◽  
Author(s):  
Thomas Müller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Motor Behavior ◽  
Brain Delivery ◽  
Antiviral Compound ◽  
Once Daily ◽  
Beneficial Effects ◽  
Central Monoamine ◽  
Preventive Effects

Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease. Its current resurgence results from an innovative, delayed uptake and extended release amantadine hydrochloride capsule, given at bedtime once daily. It is the only approved compound for reduction of involuntary movements, so called dyskinesia, in fluctuating orally levodopa treated patients. It additionally ameliorates ‘off’-intervals characterized by impaired motor behavior. These beneficial effects result from higher and more continuous brain delivery of amantadine. Future clinical research is warranted on preventive effects of this amantadine capsule combined with enzyme blockers of central monoamine oxidase B and peripheral catechol-O-methyltransferase on motor complications in orally levodopa treated patients, as all these pharmacological principles support the concept of continuous dopamine substitution.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

2010 ◽  
Vol 25 (15) ◽  
pp. 2542-2549 ◽  
Author(s):  
Robert A. Hauser ◽  
Anthony H.V. Schapira ◽  
Olivier Rascol ◽  
Paolo Barone ◽  
Yoshikuni Mizuno ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Double Blind ◽  
Once Daily ◽  
Early Parkinson’S Disease

scholarly journals Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Ji Young Yun ◽  
Young Eun Kim ◽  
Hui-Jun Yang ◽  
Han-Joon Kim ◽  
Beomseok Jeon
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Daily Regimen ◽  
Open Label ◽  
Multiple Dosing ◽  
Once Daily ◽  
Open Label Study ◽  
Dopamine Agonist Therapy ◽  
Second Period

This open-label study aimed to compare once-daily and twice-daily pramipexole extended release (PER) treatment in Parkinson’s disease (PD). PD patients on dopamine agonist therapy, but with unsatisfactory control, were enrolled. Existing agonist doses were switched into equivalent PER doses. Subjects were consecutively enrolled into either once-daily-first or twice-daily-first groups and received the prescribed amount in one or two, respectively, daily doses for 8 weeks. For the second period, subjects switched regimens in a crossover manner. The forty-four patients completed a questionnaire requesting preference during their last visit. We measured the UPDRS-III, Hoehn and Yahr stages (H&Y) in medication-on state, Parkinson’s disease sleep scale (PDSS), and Epworth Sleepiness Scale. Eighteen patients preferred a twice-daily regimen, 12 preferred a once-daily regimen, and 14 had no preference. After the trial, 14 subjects wanted to be on a once-daily regimen, 25 chose a twice-daily regimen, and 5 wanted to maintain the prestudy regimen. Main reasons for choosing the twice-daily regimen were decreased off-duration, more tolerable off-symptoms, and psychological stability. The mean UPDRS-III, H&Y, and PDSS were not different. Daytime sleepiness was significantly high in the once-daily regimen, whereas nocturnal hallucinations were more common in the twice-daily. Multiple dosing should be considered if once-daily dosing is unsatisfactory. This study is registered asNCT01515774at ClinicalTrials.gov.

Opicapone for Parkinson’s disease: clinical evidence and future perspectives

2021 ◽  
Author(s):  
Clémence Leung ◽  
Olivier Rascol ◽  
Margherita Fabbri
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Evidence ◽  
Open Label ◽  
Once Daily ◽  
Beneficial Effects ◽  
Long Acting ◽  
Post Hoc ◽  
Disease Stages ◽  
Off Time

Since 2016, opicapone (OPC), a potent third-generation, long-acting, once-daily, peripheral catechol-O-methyltransferase inhibitor, is approved as add-on to levodopa in Parkinson’s disease patients with motor fluctuations. OPC 50 mg has showed to be able in reducing OFF time by an average of about 60 min daily compared with placebo, to further reduce OFF-time of about 39 min, when switched from ENT to OPC and to be safe. These beneficial effects of OPC were maintained for 1 year. Recently, several post hoc analysis and few pilot observational open-label studies, have suggested its efficacy and wider applicability for different phenotypes of motor complications and for Parkinson’s disease stages. Here we review OPC applicability and perspectives, in the light of the more recently published analysis.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

2010 ◽  
Vol 25 (14) ◽  
pp. 2326-2332 ◽  
Author(s):  
Olivier Rascol ◽  
Paolo Barone ◽  
Robert A. Hauser ◽  
Yoshikuni Mizuno ◽  
Werner Poewe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Once Daily ◽  
Early Parkinson’S Disease

Protective effect of caffeine and/or taurine on the 6-hydroxydopamine-induced rat model of Parkinson’s disease: Behavioral and neurochemical evidence

2021 ◽  
pp. 1-9
Author(s):  
Amjad N. Abuirmeileh ◽  
Sawsan M. Abuhamdah ◽  
Asser Ashraf ◽  
Karem H. Alzoubi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Model ◽  
Motor Behavior ◽  
Rat Striatum ◽  
Ipsilateral Side ◽  
Time Points ◽  
Beneficial Effects ◽  
Behavior Response ◽  
6 Hydroxydopamine

Background: Caffeine and taurine, which possess neuro-modulatory activity happen to be consumed together as part of the constituents of energy drinks, could have beneficial effects and prevent neuronal deterioration in Parkinson’s disease (PD). Objective: This study aimed to investigate behavioral and neurochemical effects of these two agents in an animal model of PD at two time points to evaluate possible neuro-protective or neuro- modulatory effects. Methods: Stereotaxic injection of 6-hydroxydopamine (6-OHDA) in rat striatum was used to model PD-like behavior in animals. Motor behavior was assessed by a characteristic rotation behavior response to the apomorphine challenge and dopamine levels in the striatum were quantified using HPLC-ED. Results: A reduction in apomorphine induced rotations following administration of caffeine and/or taurine as compared to the untreated lesioned group (controls) was shown. Significant decreases in dopamine levels were also seen in the ipsilateral side of 6-OHDA group, this effect was not significantly reversed in caffeine and taurine treated groups. Treatments partially restored the content of DA levels in the lesioned striatum. Conclusions: Current results demonstrated beneficial effects for the combination of caffeine and taurine in PD animal model, suggesting that consumption of both agents could be a new added therapeutic target for Parkinson’s disease prevention and treatment.

Sign in / Sign up

Export Citation Format

Share Document